Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia
Issued Date
2024-01-01
Resource Type
ISSN
1040841X
eISSN
15497828
Scopus ID
2-s2.0-85197636688
Journal Title
Critical Reviews in Microbiology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Critical Reviews in Microbiology (2024)
Suggested Citation
Shein A.M.S., Hongsing P., Smith O.K., Phattharapornjaroen P., Miyanaga K., Cui L., Ishikawa H., Amarasiri M., Monk P.N., Kicic A., Chatsuwan T., Pletzer D., Higgins P.G., Abe S., Wannigama D.L. Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia. Critical Reviews in Microbiology (2024). doi:10.1080/1040841X.2024.2369948 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/99633
Title
Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia
Author's Affiliation
Yamagata Prefectural Central Hospital
Medizinische Fakultät
Mae Fah Luang University Hospital
UWA Medical School
Yamagata Prefectural University of Health Sciences
Perth Children's Hospital
Jichi Medical University
Curtin University
Sahlgrenska Akademin
Universität zu Köln
Mae Fah Luang University
University of Otago
Faculty of Medicine Ramathibodi Hospital, Mahidol University
The Sheffield Medical School
Kitasato University
Faculty of Medicine, Chulalongkorn University
The University of Sheffield
Telethon Kids Institute
Partner Site Bonn-Cologne
Medizinische Fakultät
Mae Fah Luang University Hospital
UWA Medical School
Yamagata Prefectural University of Health Sciences
Perth Children's Hospital
Jichi Medical University
Curtin University
Sahlgrenska Akademin
Universität zu Köln
Mae Fah Luang University
University of Otago
Faculty of Medicine Ramathibodi Hospital, Mahidol University
The Sheffield Medical School
Kitasato University
Faculty of Medicine, Chulalongkorn University
The University of Sheffield
Telethon Kids Institute
Partner Site Bonn-Cologne
Corresponding Author(s)
Other Contributor(s)
Abstract
Acinetobacter baumannii is a common pathogen associated with hospital-acquired pneumonia showing increased resistance to carbapenem and colistin antibiotics nowadays. Infections with A. baumannii cause high patient fatalities due to their capability to evade current antimicrobial therapies, emphasizing the urgency of developing viable therapeutics to treat A. baumannii-associated pneumonia. In this review, we explore current and novel therapeutic options for overcoming therapeutic failure when dealing with A. baumannii-associated pneumonia. Among them, antibiotic combination therapy administering several drugs simultaneously or alternately, is one promising approach for optimizing therapeutic success. However, it has been associated with inconsistent and inconclusive therapeutic outcomes across different studies. Therefore, it is critical to undertake additional clinical trials to ascertain the clinical effectiveness of different antibiotic combinations. We also discuss the prospective roles of novel antimicrobial therapies including antimicrobial peptides, bacteriophage-based therapy, repurposed drugs, naturally-occurring compounds, nanoparticle-based therapy, anti-virulence strategies, immunotherapy, photodynamic and sonodynamic therapy, for utilizing them as additional alternative therapy while tackling A. baumannii-associated pneumonia. Importantly, these innovative therapies further require pharmacokinetic and pharmacodynamic evaluation for safety, stability, immunogenicity, toxicity, and tolerability before they can be clinically approved as an alternative rescue therapy for A. baumannii-associated pulmonary infections.